Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. EyePoint Pharmaceuticals Inc shares valued at $5,954 were sold by Jones David Scott on Feb 02 ’24. At $28.49 per share, Jones David Scott sold 209 shares. The insider’s holdings dropped to 37,962 shares worth approximately $0.87 million following the completion of this transaction.
Also, Paggiarino Dario A. sold 49,325 shares, netting a total of over 1,265,539 in proceeds. Following the sale of shares at $25.66 each, the insider now holds 36,505 shares.
Before that, Jones David Scott had sold 26,017 shares from its account. In a trade valued at $660,370, the SVP & Chief Commercial Officer traded EyePoint Pharmaceuticals Inc shares for $25.38 each. Upon closing the transaction, the insider’s holdings decreased to 26,017 shares, worth approximately $0.87 million.
As published in their initiating research note from JP Morgan on January 22, 2024, EyePoint Pharmaceuticals Inc [EYPT] has been an Overweight and the price target has been revised to $35. Analysts at Mizuho started covering the stock with ‘”a Buy”‘ outlook in a report released in early November. As of April 21, 2023, Robert W. Baird has initiated its “an Outperform” rating for EYPT. Earlier on July 07, 2022, Chardan Capital Markets initiated its rating. Their recommendation was “a Buy” for EYPT stock.
Analyzing EYPT Stock Performance
During the last five days, there has been a surge of approximately 13.60%. Over the course of the year, EyePoint Pharmaceuticals Inc shares have dropped approximately -0.95%. Shares of the company reached a 52-week high of $30.99 on 02/08/24 and a 52-week low of $19.03 on 01/11/24. A 50-day SMA is recorded $24.83, while a 200-day SMA reached $15.63. Nevertheless, trading volume fell to 0.65 million shares from 0.48 million shares the previous day.
Support And Resistance Levels for EyePoint Pharmaceuticals Inc (EYPT)
According to the 24-hour chart, there is a support level at 21.98, which, if violated, would cause prices to drop to 21.06. In the upper region, resistance lies at 23.40. The next price resistance is at 23.90. RSI (Relative Strength Index) is 54.05 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.00, which suggests the price will increase in the coming days. Percent R is at 12.75%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is EyePoint Pharmaceuticals Inc subject to short interest?
Stocks of EyePoint Pharmaceuticals Inc saw a sharp rise in short interest on Mar 15, 2024 jumping by 1.83 million shares to 6.58 million. Data from Yahoo Finance shows that the short interest on Feb 15, 2024 was 4.75 million shares. A jump of 27.81% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.85 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.85.
